Literature DB >> 26722470

Expression of ITGB1 predicts prognosis in colorectal cancer: a large prospective study based on tissue microarray.

Qi-Zhi Liu1, Xian-Hua Gao1, Wen-Jun Chang2, Hai-Feng Gong1, Chuan-Gang Fu1, Wei Zhang1, Guang-Wen Cao2.   

Abstract

BACKGROUND: ITGB1 is a heterodimeric cell-surface receptor involved in cell functions such as proliferation, migration, invasion and survival. The aim of this study was to assess ITGB1 expression in colorectal cancer and correlate it with clinicopathological features, as well as to evaluate its potential prognostic significance.
MATERIALS AND METHODS: In this study, we examined the expression of ITGB1 using tissue microarrays containing analyzed specimens by immunohistochemistry. ITGB1 expression was further correlated with clinicopathological and prognostic data. The prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. A multivariate study with the Cox's proportional hazard model was used to evaluate the prognostic aspects.
RESULTS: ITGB1 expression was present in 88.5% of the analyzed specimens. Significant differences in ITGB1 expression were found between normal mucosa and carcinomas (P<0.001). High ITGB1 expression was associated with poor prognosis, and it independently correlated with shortened overall survival and disease-free survival in colorectal cancer patients (P<0.001). More so, ITGB1 expression, bowel wall invasion, lymph node metastasis and distant metastasis were independent prognostic factors for overall survival. Additionally, significant differences in ITGB1 expression were observed in adenomas and tumors from patients with familial adenomatous polyposis compared to normal colon mucosa (P<0.05)
CONCLUSION: The results of this study indicate that ITGB1 overexpression in colorectal tumors is associated with poor prognosis, as well as aggressive clinicopathological features. Therefore, ITGB1 expression could be used as potential prognostic predictor in colorectal cancer patients.

Entities:  

Keywords:  Colorectal cancer; ITGB1; prognosis; tissue microarray

Mesh:

Substances:

Year:  2015        PMID: 26722470      PMCID: PMC4680415     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  34 in total

Review 1.  Linking integrin conformation to function.

Authors:  Janet A Askari; Patrick A Buckley; A Paul Mould; Martin J Humphries
Journal:  J Cell Sci       Date:  2009-01-15       Impact factor: 5.285

2.  Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.

Authors:  Richard C Bates; David I Bellovin; Courtney Brown; Elizabeth Maynard; Bingyan Wu; Hisaaki Kawakatsu; Dean Sheppard; Peter Oettgen; Arthur M Mercurio
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

3.  LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis.

Authors:  Rich Y C Hsu; Carlos H F Chan; Jonathan D Spicer; Mathieu C Rousseau; Betty Giannias; Simon Rousseau; Lorenzo E Ferri
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

4.  Predictive value of congenital hypertrophy of the retinal pigment epithelium as a clinical marker for familial adenomatous polyposis.

Authors:  F Heyen; D G Jagelman; A Romania; Z N Zakov; I C Lavery; V W Fazio; E McGannon
Journal:  Dis Colon Rectum       Date:  1990-12       Impact factor: 4.585

Review 5.  β1-integrin: a potential therapeutic target in the battle against cancer recurrence.

Authors:  Dalit Barkan; Ann F Chambers
Journal:  Clin Cancer Res       Date:  2011-09-07       Impact factor: 12.531

6.  β1 integrin is required for anchorage-independent growth and invasion of tumor cells in a context dependent manner.

Authors:  Allana M Schooley; Natalie M Andrews; Huijun Zhao; Christina L Addison
Journal:  Cancer Lett       Date:  2011-10-30       Impact factor: 8.679

7.  KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.

Authors:  V Deschoolmeester; C Boeckx; M Baay; J Weyler; W Wuyts; E Van Marck; M Peeters; F Lardon; J B Vermorken
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

8.  Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma.

Authors:  Zhen-Bin Ding; Ying-Hong Shi; Jian Zhou; Guo-Ming Shi; Ai-Wu Ke; Shuang-Jian Qiu; Xiao-Ying Wang; Zhi Dai; Yang Xu; Jia Fan
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

9.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts.

Authors:  Catherine C Park; Hui J Zhang; Evelyn S Yao; Chong J Park; Mina J Bissell
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

10.  Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age.

Authors:  Kristian E Storli; Karl Søndenaa; Ida R K Bukholm; Idunn Nesvik; Tore Bru; Bjørg Furnes; Bjarte Hjelmeland; Knut B Iversen; Geir E Eide
Journal:  Int J Colorectal Dis       Date:  2011-05-12       Impact factor: 2.571

View more
  20 in total

1.  Integrin β1 is a critical effector in promoting metastasis and chemo-resistance of esophageal squamous cell carcinoma.

Authors:  Zhipeng Xu; Li Zou; Gang Ma; Xiaowei Wu; Furong Huang; Tingting Feng; Suqing Li; Qingfeng Lin; Xiaoting He; Zhihua Liu; Xiufeng Cao
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway.

Authors:  Lin Jin; Trung Vu; Guandou Yuan; Pran K Datta
Journal:  Cancer Res       Date:  2017-08-21       Impact factor: 12.701

3.  Tracking the Molecular Scenarios for Tumorigenic Remodeling of Extracellular Matrix Based on Gene Expression Profiling in Equine Skin Neoplasia Models.

Authors:  Przemysław Podstawski; Katarzyna Ropka-Molik; Ewelina Semik-Gurgul; Marcin Samiec; Maria Skrzyszowska; Zenon Podstawski; Tomasz Szmatoła; Maciej Witkowski; Klaudia Pawlina-Tyszko
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

4.  Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma.

Authors:  Ran Tao; Qiang Li; Xiaofei Gao; Lilin Ma
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

Review 5.  Prognostic value of increased integrin-beta 1 expression in solid cancers: a meta-analysis.

Authors:  Quanwu Sun; Chuan Zhou; Ruofei Ma; Qianhong Guo; Haiyun Huang; Jie Hao; Hong Liu; Rong Shi; Bo Liu
Journal:  Onco Targets Ther       Date:  2018-03-29       Impact factor: 4.147

6.  RelB plays an oncogenic role and conveys chemo-resistance to DLD-1 colon cancer cells.

Authors:  Xiaojun Zhou; Zhili Shan; Hengying Yang; Jingjing Xu; Wenjing Li; Feng Guo
Journal:  Cancer Cell Int       Date:  2018-11-13       Impact factor: 5.722

7.  Nanoscale imaging of the adhesion core including integrin β1 on intact living cells using scanning electron-assisted dielectric-impedance microscopy.

Authors:  Tomoko Okada; Toshihiko Ogura
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

8.  MiR-192, miR-200c and miR-17 are fibroblast-mediated inhibitors of colorectal cancer invasion.

Authors:  Volker Ast; Theresa Kordaß; Marcus Oswald; Amol Kolte; David Eisel; Wolfram Osen; Stefan B Eichmüller; Alexander Berndt; Rainer König
Journal:  Oncotarget       Date:  2018-10-30

9.  Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell.

Authors:  Xiaohui Yang; Shuai Wang; Weihua Yu; Yixiong Zheng; Yulian Wu
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

10.  BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation.

Authors:  Nadine Reischmann; Geoffroy Andrieux; Ricarda Griffin; Thomas Reinheckel; Melanie Boerries; Tilman Brummer
Journal:  Oncogene       Date:  2020-08-13       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.